European Commission logo
français français
CORDIS - Résultats de la recherche de l’UE
CORDIS

Identification and Management of Patients at Risk – Outcome and Vascular Events in Peritoneal Dialysis

Description du projet

Un programme de formation à la recherche sur la prise en charge des patients souffrant de néphropathie

La dialyse péritonéale (DP) est un traitement de substitution rénale susceptible de sauver la vie des patients souffrant de néphropathie terminale. Il existe un besoin urgent d’approches individualisées de la DP, car ces patients sont exposés à un risque plus élevé de maladies cardiovasculaires potentiellement fatales. Financé par le programme Actions Marie Skłodowska-Curie, le projet IMPROVE-PD a pour objectif de faire participer des chercheurs universitaires et industriels de premier plan à la création d’une plateforme de formation afin d’appréhender les mécanismes de la maladie cardiovasculaire due à l’inflammation chez les patients en traitement par DP et de développer des thérapies individualisées pour les personnes à risque. L’objectif est d’assurer la formation de 15 jeunes scientifiques qui vont travailler dans le cadre d’un programme européen pluridisciplinaire de formation de niveau doctorant incluant des partenaires universitaires, cliniques et industriels de renom.

Objectif

Peritoneal dialysis (PD) is an underused life saving renal replacement therapy for end-stage kidney disease. Nevertheless, PD patients remain at high risk for poor outcome, most notably excessive risk of cardiovascular disease. There is an unmet need for a risk-adjusted individualized PD approach. The IMPROVE-PD consortium provides 15 Early Stage Researchers (ESRs) in 11 partner institutes located in 7 different countries a state-of-the-art, multidisciplinary and intersectoral pan- European training programme including input from academic, clinical and industrial stakeholders. Network-wide and local training activities, individual research projects, intersectoral secondments and short laboratory visits will provide key generic skills and will prepare ESRs for future roles as highly skilled researchers in Europe. Well-phenotyped patient cohorts, and novel experimental models and techniques will be exploited by the ESRs, mentored by an excellent supervisory team, to improve future management of the PD patient at risk. This joint effort encourages productive collaboration between industrial and academic sectors though integrated projects and shared goals. Key findings will be communicated to a broad range of stakeholders through state of the art methods. IMPROVE-PD will give rise to a new generation of experts in PD with outstanding interdisciplinary research skills, intersectoral understanding and with perspective to pursue their careers in this scientific and industrial field. It will enable timely identification of the PD patient at high risk for adverse outcome, develop understanding of underlying pathomechanisms, and within an iterative process between research groups foster the development of innovative approaches to individualized treatment by targeting revealed pathomechanisms. Through these approaches, the ITN will achieve refinement of PD fluids, PD therapy and cardiovascular risk reduction.

Coordinateur

AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
Contribution nette de l'UE
€ 501 809,76
Adresse
CALLE SERRANO 117
28006 Madrid
Espagne

Voir sur la carte

Région
Comunidad de Madrid Comunidad de Madrid Madrid
Type d’activité
Research Organisations
Liens
Coût total
€ 501 809,76

Participants (11)

Partenaires (11)